RT Journal Article
SR Electronic
T1 Differences in risk for SARS-CoV-2 infection among healthcare workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.30.21254653
DO 10.1101/2021.03.30.21254653
A1 K. Miriam Elfström
A1 Jonas Blomqvist
A1 Peter Nilsson
A1 Sophia Hober
A1 Elisa Pin
A1 Anna Månberg
A1 Ville N. Pimenoff
A1 Laila Sara Arroyo Mühr
A1 Kalle Conneryd Lundgren
A1 Joakim Dillner
YR 2021
UL http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254653.abstract
AB Healthcare workers (HCWs) are a risk group for SARS-CoV-2 infection, but which healthcare work that conveys risk and to what extent such risk can be prevented is not clear. Starting on April 24th, 2020, all employees at work (n=15,300) at the Karolinska University Hospital, Stockholm, Sweden were invited and 92% consented to participate in a SARS-CoV-2 cohort study. Complete SARS-CoV-2 serology was available for n=12,928 employees and seroprevalences were analyzed by age, sex, profession, patient contact, and hospital department. Relative risks were estimated to examine the association between type of hospital department as a proxy for different working environment exposure and risk for seropositivity, adjusting for age, sex, sampling week, and profession. Wards that were primarily responsible for COVID-19 patients were at increased risk (adjusted OR 1.95 (95% CI 1.65-2.32) with the notable exception of the infectious diseases and intensive care units (adjusted OR 0.86 (95% CI 0.66-1.13)), that were not at increased risk despite being highly exposed. Several units with similar types of work varied greatly in seroprevalences. Among the professions examined, nurse assistants had the highest risk (adjusted OR 1.62 (95% CI 1.38-1.90)). Although healthcare workers, in particular nurse assistants, who attend to COVID-19 patients are a risk group for SARS-CoV-2 infection, several units caring for COVID-19 patients had no excess risk. Large variations in seroprevalences among similar units suggest that healthcare work-related risk of SARS-CoV-2 infection may be preventable.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04411576Funding StatementSupport was obtained from the Karolinska University Hospital, the County Council of Stockholm, Erling-Persson family foundation, KTH Royal Institute of Technology, Creades, and SciLifeLab. The funding agencies have had no role in the design, execution or interpretation of the study or in the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Ethical Review Agency of Sweden (Decision number 2020-01620).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon request to Dr. Joakim Dillner, joakim.dillner{at}sll.se.